What Does Early Data from BriaCell’s Bria-IMT Combination Study with KEYTRUDA Show?

BriaCell Therapeutics Corp. (TSX:BCT, OTCQB:BCTXF) recently released some initial results from the company’s Phase IIa combination clinical trials for their Bria-IMT immunotherapy. The treatment is designed to treat advanced breast cancer. An article by the Chimera Research Group broke down the preliminary results for BriaCell’s Phase IIa clinical trials.

When patients were treated with the monotherapy, BriaCell was able to match 15 out of 23 patients with at least one HLA match, which may seem like a small number. However, the company’s immunotherapy is matching with  50 percent of patients, creating a large patient population that could benefit from their treatment and could lead to faster enrolment in the program. The article went on to point out that efficacy in monotherapies can be difficult to measure, but BriaCell has documented immune responses in patients that have matched with a Bria-IMT HLA and the company has had four patients experience tumor shrinkage when using the therapy.

The article went on to describe the combination therapy results when the Bria-IMT was paired with Merck’s (NYSE:MRK) KEYTRUDA® therapy. BriaCell has had five patients enrolled in the program and so far none of the patients have experienced any adverse effects from the therapy. While it is too early to determine the efficacy of the treatment, four of the five patients have remained in the treatment, which is significant as patients only remain on the treatment as long as the disease is not progressing and the treatment remains tolerable.

In essence the early results are confirming that the treatment is safe. BriaCell is expecting to speak to the efficacy of its treatment in Q1 2019 as they release more updates on their trials.

To view the full article, click here.

Click here to connect with BriaCell Therapeutics Corp. (TSX:BCT, OTCQB:BCTXF) for an Investor Presentation. 

Source: www.chimeraresearchgroup.com